Proficio Capital Partners LLC bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) during ...

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

BURLINGTON, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Hyku Biosciences, a pioneer in precision medicine, today announced the appointment of Keith Wilcoxen, PhD, as Chief Scientific Officer. Dr.

If you work in the biotech industry, you might know the name Alex Denner. If not, his name probably doesn’t ring a bell. ...

Neurocrine Biosciences ... and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with ...

Existing research indicates that the accuracy of a Parkinson’s disease diagnosis hovers between 55% and 78% in the first five years of assessment. That’s partly because Parkinson’s sibling movement ...

TD Cowen analyst Phil Nadeau maintained a Hold rating on Xoma (XOMA – Research Report) yesterday. The company’s shares closed yesterday at ...

The approval is also a milestone for Neurocrine Bioscience, as it will be the company’s first ever marketed product – and is tipped to reach peak annual sales in excess of $1 billion.